Morepen Q2FY27 Results: Standalone PAT Up 442%, CDMO Scales
SumanSpeaks Independent Capital Markets & Geopolitical Intelligence PHARMACEUTICALS | Q2FY27 EARNINGS Morepen Laboratories Q2FY27: Standalone PAT Up 442%, CDMO Turns Commercial A standalone profit of ₹77.87 crore against ₹14.38 crore a year ago, consolidated profit of ₹88.89 crore, and CDMO revenue up roughly 334% to about ₹253 crore. Add exports of ₹397 crore for the quarter and 20 million glucose meters in the field, and Morepen no longer fits the label of a sleepy API maker. Morepen Laboratories (₹99.15) (NSE: MOREPENLAB | BSE: 500288 | ISIN: INE083A01026) did something rare in the September quarter. It earned a standalone profit of ₹77.87 crore, against ₹14.38 crore a year ago, a rise of 442%. On a consolidated basis, net profit more than doubled to ₹88.89 crore, up 117.48%, on revenue from operations of ₹746.50 crore, up 81.4%. A 442% jump sounds like a typo until you look at the base. The percentage is the headline, but the rupee figure is the part worth framing:...